The fully linked HTML version of this article has now been published.
Development ePress online publication date 23 Jun 2005
doi: 10.1242/dev.01914
Research article: Development and disease
Abnormalities in cartilage and bone development in the Apert syndrome FGFR2+/S252W mouse
Yingli Wang,
Ran Xiao,
Fan Yang,
Baktiar O. Karim,
Anthony J. Iacovelli,
Juanliang Cai,
Charles P. Lerner,
Joan T. Richtsmeier,
Jen M. Leszl,
Cheryl A. Hill,
Kai Yu,
David M. Ornitz,
Jennifer Elisseeff,
David L. Huso,
and
Ethylin Wang Jabs*
* Author for correspondence (e-mail: ejabs1{at}jhem.jhmi.edu)
Apert syndrome is an autosomal dominant disorder characterized by malformations of the skull, limbs and viscera. Two-thirds of affected individuals have a S252W mutation in fibroblast growth factor receptor 2 (FGFR2). To study the pathogenesis of this condition, we generated a knock-in mouse model with this mutation. The Fgfr2+/S252W mutant mice have abnormalities of the skeleton, as well as of other organs including the brain, thymus, lungs, heart and intestines. In the mutant neurocranium, we found a midline sutural defect and craniosynostosis with abnormal osteoblastic proliferation and differentiation. We noted ectopic cartilage at the midline sagittal suture, and cartilage abnormalities in the basicranium, nasal turbinates and trachea. In addition, from the mutant long bones, in vitro cell cultures grown in osteogenic medium revealed chondrocytes, which were absent in the controls. Our results suggest that altered cartilage and bone development play a significant role in the pathogenesis of the Apert syndrome phenotype.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M.-C. Ting, N. L. Wu, P. G. Roybal, J. Sun, L. Liu, Y. Yen, and R. E. Maxson Jr
EphA4 as an effector of Twist1 in the guidance of osteogenic precursor cells during calvarial bone growth and in craniosynostosis
Development,
March 1, 2009;
136(5):
855 - 864.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Miraoui, K. Oudina, H. Petite, Y. Tanimoto, K. Moriyama, and P. J. Marie
Fibroblast Growth Factor Receptor 2 Promotes Osteogenic Differentiation in Mesenchymal Cells via ERK1/2 and Protein Kinase C Signaling
J. Biol. Chem.,
February 20, 2009;
284(8):
4897 - 4904.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Dutt, H. B. Salvesen, T.-H. Chen, A. H. Ramos, R. C. Onofrio, C. Hatton, R. Nicoletti, W. Winckler, R. Grewal, M. Hanna, et al.
Drug-sensitive FGFR2 mutations in endometrial carcinoma
PNAS,
June 24, 2008;
105(25):
8713 - 8717.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Giritharan, S. Talbi, A. Donjacour, F. Di Sebastiano, A. T Dobson, and P. F Rinaudo
Effect of in vitro fertilization on gene expression and development of mouse preimplantation embryos
Reproduction,
July 1, 2007;
134(1):
63 - 72.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Li, D. A. Scott, E. Hatch, X. Tian, and S. L. Mansour
Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development
Development,
January 1, 2007;
134(1):
167 - 176.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. McDowell, B. A. Frazier, D. R. Studelska, K. Giljum, J. Chen, J. Liu, K. Yu, D. M. Ornitz, and L. Zhang
Inhibition or Activation of Apert Syndrome FGFR2 (S252W) Signaling by Specific Glycosaminoglycans
J. Biol. Chem.,
March 17, 2006;
281(11):
6924 - 6930.
[Abstract]
[Full Text]
[PDF]
|
 |
|
© The Company of Biologists Ltd 2005